GlaxoSmithKline Avoids Market for Lemons by Buying Collaborators

Published: May 24, 2012

GlaxoSmithKline Plc (GSK) may find its next acquisition target where the U.K. drugmaker found the last two: among more than a dozen companies it collaborates with to develop new treatments. Glaxo has stakes in more than 10 publicly-traded companies, including DiaDexus Inc. (DDXS), which develops diagnostics for detecting heart attack and stroke risk, according to data compiled by Bloomberg. The London-based company also has stakes in an undisclosed number of closely held businesses.

Back to news